Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 5,514.5% in October

Ensysce Biosciences, Inc. (NASDAQ:ENSC) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 6,350,000 shares, an increase of 5,514.5% from the October 15th total of 113,100 shares. Based on an average trading volume of 27,160,000 shares, the short-interest ratio is presently 0.2 days. Approximately 43.4% of the shares of the company are short sold.

Ensysce Biosciences Trading Up 5.1 %

ENSC opened at $0.71 on Thursday. The business’s 50 day moving average is $0.36 and its 200-day moving average is $0.45. The stock has a market cap of $6.25 million, a PE ratio of -0.39 and a beta of 0.63. Ensysce Biosciences has a twelve month low of $0.14 and a twelve month high of $2.06.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.37. The company had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $0.25 million. Ensysce Biosciences had a negative return on equity of 559.68% and a negative net margin of 179.26%. As a group, analysts forecast that Ensysce Biosciences will post -1.43 EPS for the current year.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.